Increased plasma levels of galectin-1 in pancreatic cancer: potential use as biomarker

Mostra el registre complet Registre parcial de l'ítem

• dc.contributor.author Martínez Bosch, Neus
• dc.contributor.author Barranco Priego, Luis Eugenio
• dc.contributor.author Orozco, Carlos Alberto
• dc.contributor.author Moreno, Mireia
• dc.contributor.author Visa Turmo, Laura
• dc.contributor.author Iglesias Coma, Mar
• dc.contributor.author Oldfield, Lucy
• dc.contributor.author Neoptolemos, John
• dc.contributor.author Greenhalf, William
• dc.contributor.author Earl, Julie
• dc.contributor.author Carrato, Alfredo
• dc.contributor.author Costello, Eithne
• dc.contributor.author Navarro Medrano, Pilar
• dc.date.accessioned 2019-06-27T07:33:50Z
• dc.date.available 2019-06-27T07:33:50Z
• dc.date.issued 2018
• dc.description.abstract Pancreatic ductal adenocarcinoma (PDA) is the most frequent type of pancreatic cancer and one of the deadliest diseases overall. New biomarkers are urgently needed to allow early diagnosis, one of the only factors that currently improves prognosis. Here we analyzed whether the detection of circulating galectin-1 (Gal-1), a soluble carbohydrate-binding protein overexpressed in PDA tissue samples, can be used as a biomarker for PDA. Gal-1 levels were determined by ELISA in plasma from healthy controls and patients diagnosed with PDA, using three independent cohorts. Patients with chronic pancreatitis (CP) were also included in the study to analyze the potential of Gal-1 to discriminate between cancer and inflammatory process. Plasma Gal-1 levels were significantly increased in patients with PDA as compared to controls in all three cohorts. Gal-1 sensitivity and specificity values were similar to that of the CA19-9 biomarker (the only FDA-approved blood test biomarker for PDA), and the combination of Gal-1 and CA19-9 significantly improved their individual discriminatory powers. Moreover, high levels of Gal-1 were associated with lower survival in patients with non-resected tumors. Collectively, our data indicate a strong potential of using circulating Gal-1 levels as a biomarker for detection and prognostics of patients with PDA.
• dc.format.mimetype application/pdf
• dc.identifier.citation Martinez-Bosch N, Barranco LE, Orozco CA, Moreno M, Visa L, Iglesias M. et al. Increased plasma levels of galectin-1 in pancreatic cancer: potential use as biomarker. Oncotarget. 2018 Aug 31;9(68):32984-32996. DOI: 10.18632/oncotarget.26034
• dc.identifier.doi http://dx.doi.org/10.18632/oncotarget.26034
• dc.identifier.issn 1949-2553
• dc.identifier.uri http://hdl.handle.net/10230/41877
• dc.language.iso eng
• dc.publisher Impact Journal
• dc.rights Copyright : © 2018 Martinez-Bosch et al. This article is distributed under the terms of the Creative Commons Attribution License (CC-BY), https://creativecommons.org/licenses/by/3.0/, which permits unrestricted use and redistribution provided that the original author and source are credited
• dc.rights.accessRights info:eu-repo/semantics/openAccess
• dc.rights.uri https://creativecommons.org/licenses/by/3.0/
• dc.subject.keyword Biomarker
• dc.subject.keyword Chronic pancreatitis
• dc.subject.keyword Galectin-1
• dc.subject.keyword Pancreatic cancer
• dc.title Increased plasma levels of galectin-1 in pancreatic cancer: potential use as biomarker
• dc.type info:eu-repo/semantics/article
• dc.type.version info:eu-repo/semantics/publishedVersion